EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
复制标题
DOI：
10.1016/j.jhep.2018.03.019
复制
发表时间：
2018-07-01
影响因子：
25.7
通讯作者：
中科院分区：
文献类型：
--
作者：
肝癌是全球第五大常见癌症，也是第二大癌症相关死亡原因。肝细胞癌约占原发性肝癌的90%，是一个主要的全球健康问题。以下临床实践指南将为肝细胞癌患者的临床管理提供最新建议，并对所有相关数据进行深入回顾，从而得出本文的结论。(C) 2018年欧洲肝脏研究协会。Elsevier B.V.版权所有。
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein. (C) 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.